HIV prevention, treatment, and care services for people who inject drugs: a systematic review of global, regional, and national coverage

	Tweet

Background
Previous reviews have examined the existence of HIV prevention, treatment, and care services for injecting drug users (IDUs) worldwide, but they did not quantify the scale of coverage. We undertook a systematic review to estimate national, regional, and global coverage of HIV services in IDUs.

Methods
We did a systematic search of peer-reviewed (Medline, BioMed Central), internet, and grey-literature databases for data published in 2004 or later. A multistage process of data requests and verification was undertaken, involving UN agencies and national experts. National data were obtained for the extent of provision of the following core interventions for IDUs: needle and syringe programmes (NSPs), opioid substitution therapy (OST) and other drug treatment, HIV testing and counselling, antiretroviral therapy (ART), and condom programmes. We calculated national, regional, and global coverage of NSPs, OST, and ART on the basis of available estimates of IDU population sizes.

Findings
By 2009, NSPs had been implemented in 82 countries and OST in 70 countries; both interventions were available in 66 countries. Regional and national coverage varied substantially. Australasia (202 needle—syringes per IDU per year) had by far the greatest rate of needle—syringe distribution; Latin America and the Caribbean (0·3 needle—syringes per IDU per year), Middle East and north Africa (0·5 needle—syringes per IDU per year), and sub-Saharan Africa (0·1 needle—syringes per IDU per year) had the lowest rates. OST coverage varied from less than or equal to one recipient per 100 IDUs in central Asia, Latin America, and sub-Saharan Africa, to very high levels in western Europe (61 recipients per 100 IDUs). The number of IDUs receiving ART varied from less than one per 100 HIV-positive IDUs (Chile, Kenya, Pakistan, Russia, and Uzbekistan) to more than 100 per 100 HIV-positive IDUs in six European countries. Worldwide, an estimated two needle—syringes (range 1—4) were distributed per IDU per month, there were eight recipients (6—12) of OST per 100 IDUs, and four IDUs (range 2—18) received ART per 100 HIV-positive IDUs.

Interpretation
Worldwide coverage of HIV prevention, treatment, and care services in IDU populations is very low. There is an urgent need to improve coverage of these services in this at-risk population.

Funding
UN Office on Drugs and Crime; Australian National Drug and Alcohol Research Centre, University of New South Wales; and Australian National Health and Medical Research Council.

###

Dr Bradley M Mathers MBChB
Prof Louisa Degenhardt PhD
Hammad Ali MBBS
Lucas Wiessing MSc
Prof Matthew Hickman FFPHM
Prof Richard P Mattick PhD
Bronwyn Myers PhD
Atul Ambekar MD
Prof Steffanie A Strathdee PhD for the 2009 Reference Group to the UN on HIV and Injecting Drug Use

The Lancet, Volume 375, Issue 9719, Pages 1014 - 1028, 20 March 2010
doi:10.1016/S0140-6736(10)60232-2

RELATED STORIES:
FDA Advisory Panel Approves Home HIV Test Kit   FDA Approves New In-Home HIV Test   Home HIV test advances   Survey Reveals Support for Over-the Counter HIV Testing   F.D.A. Panel Weighs Preventive Use of H.I.V. Drug   Stem Cell Therapy Shows Promise in Fight Against HIV   Progress against HIV thwarted by patients’ unmet needs   California to test pill for HIV prevention   Mechanism of HIV spread has potential for future drug therapy   Seeking HIV treatment clues in the neem tree   HIV Prevention Pill’s Value Varies by Target   Using AIDS drugs to prevent infection: a bargain?

Comments

[ + Post Your Own ]

Now you're in the public comment zone. What follows is not Armenian Medical Network's stuff; it comes from other people and we don't vouch for it. A reminder: By using this Web site you agree to accept our Terms of Service. Click here to read the Rules of Engagement.

There are no comments for this entry yet. [ + Comment here + ]